BCR and prostate carcinoma: Furthermore, PROTAC technology has shown promising results in overcoming acquired drug resistance as shown by targeting breakpoint cluster region protein- (BCR-) ABL to treat imatinib-resistant chronic myelomonocytic leukemia (Shimokawa et al., 2017), androgen receptor to treat enzalutamide-resistant prostate cancer (Shibata et al., 2018), and Bruton’s tyrosine kinase to treat ibrutinib-resistant lymphoma (Tinworth et al., 2019).